Empowering Success: Strategic Partnership Summit (Beijing) Successfully Concludes
On the afternoon of April 29, 2025, the "Empowering Success: Strategic Partnership Summit (Beijing Edition)" hosted by Shenzhen Surgsci Medical Ltd. and Beijing Surgsci Medical Technology Co., Ltd., successfully took place in Beijing. The event brought together representatives of distributors and agents specializing in surgical consumables across various fields, including general surgery, thoracic surgery, gastrointestinal surgery, oncological surgery, hepatobiliary surgery, urology, and gynecology. The summit focused on groundbreaking innovations in medical device technology and market collaboration opportunities, charting a path toward high-quality development in the medical industry.
The summit aimed to provide customers with in-depth insights into the brand, products, and corporate profile of Surgsci Medical. It showcased the company’s innovative product matrix in minimally invasive surgery and urology. Key products, such as ultrasonic scalpels, staplers, trocars, and ureteral metallic covered stents, were highlighted through detailed technical analysis, clinical application cases, and market prospects. The event provided Beijing’s distributor partners with comprehensive information support.
Key Highlights of the Summit:
Strategic Planning: The opening address by Mr. Wang, General Manager of Beijing Surgsci Medical, elaborated on the company’s strategic initiatives for the Beijing-Tianjin-Hebei region. He emphasized the importance of innovation driven by clinical needs.
Brand Empowerment: Li, Surgsci Medical’s Northern Regional Sales Director, provided a systematic overview of the company’s development trajectory, future plans, R&D framework, and quality management standards, enhancing partner awareness of the company’s technological capabilities.
Product Insights: Several sales leaders from the Northern Region delivered engaging presentations on innovative product lines:
Tian: Analysis and clinical applications of the Surgsci Ultrasonic Scalpel.
Zhang: Single-use linear cutting staplers and their clinical benefits.
Xiao: Metallic covered ureteral stent systems and application cases.
The summit fostered lively exchanges among attendees, who showed great interest in the showcased innovative products and engaged in in-depth discussions on regional procurement policies and channel collaboration models. Many expressed immediate readiness for cooperation, anticipating fruitful partnerships with Surgsci Medical to benefit regional markets and bring quality domestic medical solutions to patients more quickly.
Creating Core Value and Strengthening Partnerships:
Surgsci Medical emphasized the delivery of comprehensive solutions in minimally invasive surgery, providing partners with a one-stop service system for surgical innovations. The company is devoted to building long-term strategic relationships based on mutual benefit and shared growth.
Mr. Feng Gengchao, General Manager of Surgsci Medical, highlighted: “In formulating market strategies, the primary consideration is always the interests of our partners and clients, followed by our sales teams, and ultimately the company itself.” Surgsci Medical’s “customer-first” philosophy guides employees’ daily actions and serves as the cornerstone of the organization’s ethos.
To ensure exceptional service for clients and partners, Surgsci Medical has established professional service teams to cater to customer demands promptly. These experts routinely visit end-users for product maintenance, surgical tracking, and training, supporting distributors with clinical guidance and addressing other needs. Additionally, Surgsci Medical’s medical-engineering transformation team actively engages with hospital departments and partners, bridging innovation and practical application, while assisting in patent processes, academic publication, and research development.
The summit’s success further enriched the industry’s understanding of Surgsci Medical and bolstered its groundwork for future market growth and collaboration. Committed to improving health and quality of life, Surgsci Medical aims to empower medical professionals, benefit patients, and continuously explore clinical needs and market opportunities for enhanced healthcare solutions.
Surgsci Product Series | Ultrasonic Scalpel System
In recent years, advancements in surgical technology have driven the development of smarter and more precise medical equipment. Among these, the ultrasonic scalpel has become an essential tool for surgeons due to its exceptional performance in cutting soft tissues and achieving hemostasis. Compared to traditional electrosurgical devices, ultrasonic scalpels utilize high-frequency vibrations to minimize thermal damage to tissues, ensuring more accurate operations and speeding up postoperative recovery. With ongoing innovations, ultrasonic scalpels are steering modern surgeries towards being minimally invasive and intelligent, becoming indispensable in modern operating rooms.
Supported by key research projects under the National Ministry of Science and Technology and major technical initiatives from Shenzhen, Surgsci has leveraged deep technical expertise and adopted a full-stack independent R&D model to launch a new generation of AI-powered ultrasonic scalpel systems. These systems integrate intelligent algorithms with precise engineering to enhance surgical safety and operational efficiency, offering medical professionals an exceptional surgical experience.
The core host of the system is equipped with a high-performance Neural Processing Unit (NPU) with computing power of 3.6 TOPS, comparable to small AI workstations. The system incorporates five advanced AI algorithms ensuring precision and efficiency in surgery:
Tissue Adaptive Cutting Algorithm (tACA): Precisely adjusts and adapts to tissue requirements for high surgical standards.
Tissue Cutting Alert Algorithm (tCAA): Provides real-time alerts, reducing risks of tissue damage.
Metal Collision Brake Algorithm (mCBA): Instantly senses collisions, ensuring instrument safety.
Intelligent Overheat Alert Algorithm (iOTA): Monitors temperatures to prevent overheating.
Low-Temperature Cutting Control Algorithm (cCCA): Reduces heat damage, enhancing recovery speeds.
Additionally, the system supports four cutting modes: Standard™, Comforta™, Sport™, and Turbo™, optimized to meet diverse surgical needs. Each mode has undergone extensive clinical training and fine-tuning for personalized application in various scenarios.
Gun-type and Scissor-type Shears
Surgsci offers gun-type and scissor-type shears, catering to both laparoscopic and open surgeries. The clamp design ensures accurate cutting and stable gripping, making them suitable for precise dissection and tissue separation. Advanced heat conduction reduction technology minimizes tissue damage, enhancing surgical efficiency and safety for precision medicine.
Breaking Material Technology Barriers
Specialized TC4 Titanium Alloy for Ultrasonic Scalpels: Boasts superior fatigue performance and ultra-low ultrasonic attenuation, surpassing imported materials and achieving domestic substitution, breaking technological monopolies.
AI Low-Temperature Algorithm and Optimized Closed Clamp Design: Address misting issues, controlling vapor direction for clearer surgical vision and safer operations.
Non-Coating Anti-Adhesion Technology: Innovations beyond traditional PTFE coatings create titanium alloy anti-adhesion surfaces for improved durability and surgical experience.
Ultrasonic Scalpel Empowers Robotic Surgery Innovations
As laparoscopic robots become the future of surgeries, Surgsci has partnered with "Tuodao" to develop a 54cm long ultrasonic scalpel, tailored for Tuodao surgical robots, within just three months. This breakthrough has garnered widespread acclaim in clinical applications, marking a significant advancement in surgical robot technology. It highlights the necessity of deep integration between traditional medical device manufacturers and robotic technologies. Surgsci will continue advancing robotic surgical instruments and high-end energy platforms, exploring technological boundaries to innovate in the industry.
Invite Partnerships for a High-End Medical Future
Surgsci’s ultrasonic scalpel system has received MDR (EU Medical Device Regulation) certification, meeting international standards and successfully entering the global market. We aim to drive surgical innovations, offering advanced solutions for hospitals and surgeons. We invite national and international partners to share technological achievements. Contact us to explore innovative applications and empower precision minimally invasive surgeries.
Surgsci Medical Ultrasonic Surgery Instruments Receive MDR Certification
On April 8, 2025, Surgsci Medical proudly announced that its independently developed ultrasonic surgery instruments successfully achieved certification under the European Union Medical Device Regulation (MDR, Regulation (EU) 2017/745). This certification, issued by the internationally recognized TÜV Rheinland Group, represents a significant milestone for Surgsci Medical, showcasing its continued leadership in global medical device compliance and quality standards.
Additionally, the company’s Disposable Laparoscopic Trocar, Disposable Specimen Retrieval Bag, and Veress Needles have also been awarded MDR certification, highlighting Surgsci Medical’s commitment to providing comprehensive and innovative surgical solutions.
As one of the strictest regulatory frameworks introduced in the last two decades, the MDR is renowned for its rigorous technical standards and compliance requirements. Encompassing numerous technical criteria—including clinical data traceability and comprehensive lifecycle management of products—it lays a strong groundwork for safety and quality within the medical device industry. After an intensive eight-month evaluation of its design, manufacturing systems, and clinical validation processes, Surgsci Medical’s ultrasonic surgery instruments successfully passed all certification requirements, demonstrating the company’s excellence in research, production, and quality management.
Innovative Performance and Intelligence: Five AI Algorithms and Four Cutting Modes
The ultrasonic surgery instruments from Surgsci Medical are built on the foundation of national research projects and years of technological expertise. Developed through a fully autonomous R&D model, these instruments represent the next generation of surgical technology.
The system’s central processing unit is powered by a high-performance NPU (neural processing unit) processor, achieving up to 3.6 TOPS (trillion operations per second) in floating-point calculations and data processing—comparable to small AI workstations. With advanced technical architecture, it integrates five cutting-edge AI algorithms to ensure precision and safety while significantly enhancing operational efficiency. This system provides medical professionals with a seamless and highly efficient user experience.
Key AI Algorithms:
Tissue Adaptive Cutting Algorithm (tACA): Enables precise cutting with adaptive adjustments, setting a new standard for precision in tissue surgeries.
Tissue Cut-off Alert Algorithm (tCAA): Delivers real-time alerts to minimize tissue damage risk.
Metal Collision Brake Algorithm (mCBA): Instantly detects and halts collisions for enhanced device safety.
Intelligent Overheat Alarm Algorithm (iOTA): Monitors temperature in real-time, providing timely protective interventions.
Cold Cutting Control Algorithm (cCCA): Allows for precise cold cutting, reducing thermal damage and aiding faster recovery.
Four Cutting Modes: The system also features four operational modes—Standard™, Comforta™ (low smoke coagulation), Sport™ (fast cutting), and Turbo™ (ultra-fast cutting)—which are optimized to meet the diverse requirements of different surgical departments. These modes are tailored through extensive clinical training and ensure superior performance for various surgical scenarios, improving efficiency and user convenience.
Moreover, Surgsci Medical’s proprietary SoniSeal™ technology elevates vessel sealing capabilities, enabling reliable closure of blood vessels up to 7mm in diameter and extending the clinical applications of the ultrasonic surgery instruments.
From Shenzhen to Operating Rooms Worldwide
From its state-of-the-art laboratories in Shenzhen to operating rooms across Europe, Surgsci Medical demonstrates its commitment to advancing China’s medical device industry through groundbreaking technology and uncompromising quality. The successful MDR certification not only overcomes international technical barriers but also sets a new benchmark for industry standards. This achievement is expected to accelerate the global adoption of Surgsci Medical’s ultrasonic surgery instruments and enhance the company’s competitive position in the international medical device market.
Surgsci Medical Ultrasonic Surgery Instruments Receive MDR Certification
On April 8, 2025, Surgsci Medical proudly announced that its independently developed ultrasonic surgery instruments successfully achieved certification under the European Union Medical Device Regulation (MDR, Regulation (EU) 2017/745). This certification, issued by the internationally recognized TÜV Rheinland Group, represents a significant milestone for Surgsci Medical, showcasing its continued leadership in global medical device compliance and quality standards.
Additionally, the company’s Disposable Laparoscopic Trocar, Disposable Specimen Retrieval Bag, and Veress Needles have also been awarded MDR certification, highlighting Surgsci Medical’s commitment to providing comprehensive and innovative surgical solutions.
As one of the strictest regulatory frameworks introduced in the last two decades, the MDR is renowned for its rigorous technical standards and compliance requirements. Encompassing numerous technical criteria—including clinical data traceability and comprehensive lifecycle management of products—it lays a strong groundwork for safety and quality within the medical device industry. After an intensive eight-month evaluation of its design, manufacturing systems, and clinical validation processes, Surgsci Medical’s ultrasonic surgery instruments successfully passed all certification requirements, demonstrating the company’s excellence in research, production, and quality management.
Innovative Performance and Intelligence: Five AI Algorithms and Four Cutting Modes
The ultrasonic surgery instruments from Surgsci Medical are built on the foundation of national research projects and years of technological expertise. Developed through a fully autonomous R&D model, these instruments represent the next generation of surgical technology.
The system’s central processing unit is powered by a high-performance NPU (neural processing unit) processor, achieving up to 3.6 TOPS (trillion operations per second) in floating-point calculations and data processing—comparable to small AI workstations. With advanced technical architecture, it integrates five cutting-edge AI algorithms to ensure precision and safety while significantly enhancing operational efficiency. This system provides medical professionals with a seamless and highly efficient user experience.
Key AI Algorithms:
Tissue Adaptive Cutting Algorithm (tACA): Enables precise cutting with adaptive adjustments, setting a new standard for precision in tissue surgeries.
Tissue Cut-off Alert Algorithm (tCAA): Delivers real-time alerts to minimize tissue damage risk.
Metal Collision Brake Algorithm (mCBA): Instantly detects and halts collisions for enhanced device safety.
Intelligent Overheat Alarm Algorithm (iOTA): Monitors temperature in real-time, providing timely protective interventions.
Cold Cutting Control Algorithm (cCCA): Allows for precise cold cutting, reducing thermal damage and aiding faster recovery.
Four Cutting Modes: The system also features four operational modes—Standard™, Comforta™ (low smoke coagulation), Sport™ (fast cutting), and Turbo™ (ultra-fast cutting)—which are optimized to meet the diverse requirements of different surgical departments. These modes are tailored through extensive clinical training and ensure superior performance for various surgical scenarios, improving efficiency and user convenience.
Moreover, Surgsci Medical’s proprietary SoniSeal™ technology elevates vessel sealing capabilities, enabling reliable closure of blood vessels up to 7mm in diameter and extending the clinical applications of the ultrasonic surgery instruments.
From Shenzhen to Operating Rooms Worldwide
From its state-of-the-art laboratories in Shenzhen to operating rooms across Europe, Surgsci Medical demonstrates its commitment to advancing China’s medical device industry through groundbreaking technology and uncompromising quality. The successful MDR certification not only overcomes international technical barriers but also sets a new benchmark for industry standards. This achievement is expected to accelerate the global adoption of Surgsci Medical’s ultrasonic surgery instruments and enhance the company’s competitive position in the international medical device market.
The Inaugural Meeting and First Academic Conference of the Minimally Invasive Surgery Committee of the Shenzhen Biomedical Engineering Society Successfully Convened
On the afternoon of March 16, 2025, the Inaugural Meeting and First Academic Conference of the Minimally Invasive Surgery Committee of the Shenzhen Biomedical Engineering Society (hereinafter referred to as the "Committee") were solemnly held at the Lihu Campus of Shenzhen University. The event was organized by the Shenzhen Biomedical Engineering Society, co-organized by Shenzhen Segsais Medical Technology Co., Ltd., and brought together over a hundred representatives from Shenzhen's medical, industrial, and academic communities to witness the birth of this milestone academic platform in the field of minimally invasive surgery.
The conference was hosted by Zheng Zhe, the dedicated Secretary-General of the Shenzhen Biomedical Engineering Society, and attended by notable figures such as Professor Chen Siping, former Vice Chairman of the Shenzhen Political Consultative Conference, former Vice President of Shenzhen University, and founding former president of the society; Professor Dan Guo, Vice President of the society; Professor He De, Director of the Department of General Surgery at the Second Affiliated Hospital of Shenzhen University; and Feng Gengchao, General Manager of Shenzhen Segsais Medical Technology Co., Ltd. Guests included heads of surgical and related departments from major medical institutions in Shenzhen, scholars from universities, representatives of investment institutions, and industry experts, demonstrating a deeply integrated academic framework of "medicine, academia, research, industry, and finance."
After nearly three months of intensive preparation, the candidate list for the committee leadership was finalized. During the preparation phase, Professor He De and Dr. Feng Gengchao convened experts from multiple fields in Shenzhen, including clinical doctors, enterprise representatives, and university researchers, for in-depth discussions. The nominated candidates represented 60% of clinical doctors from Shenzhen's major medical institutions, along with outstanding individuals from universities, investment institutions, and enterprises.
At the meeting, Professor Dan Guo announced the approval documents for the establishment of the committee and emphasized that the preparations strictly adhered to the society's charter, with all conditions being fully met. Subsequently, through elections, the first committee members were successfully selected, laying a solid foundation for the formal establishment of the committee. The details are as follows:
Chairperson: He De (Director of General Surgery, Bao’an People's Hospital Group, Shenzhen)
Vice Chairpersons: Feng Gengchao, Zhang Yusen, Zong Hua, Wu Yang, Yue Guanghui, Geng Wen, Lü Guoqing, Wu Xiaobin, Luo Shou, Qiao Kun, Wang Shuhan, Wang Liming
Secretary-General: Feng Gengchao
Deputy Secretary-General: Li Zhijian
Standing Members: Wang Haibo, Chen Zhenrui, Li Zhijian, Hu Nan, and 26 others
Members: Zeng Guangyan, Lai Xiaodan, and 32 others
Professor Chen Siping presented the plaque to the committee and issued the appointment certificate to the chairperson, while Professor Dan Guo and Dong Lei, Deputy Director of the Shenzhen University Medical Innovation and Achievement Transformation Center, issued appointment certificates to the vice chairpersons.
In his inaugural speech, Chairperson He De expressed heartfelt gratitude for the trust of all members and solemnly committed to fulfilling future responsibilities. He stated that the establishment of the Minimally Invasive Surgery Committee marks an important practice in interdisciplinary collaboration, aiming to integrate resources from multiple disciplines, establish a high-level academic exchange platform, and elevate medical-engineering interdisciplinary cooperation to new heights. The committee will focus on key bottleneck issues in minimally invasive technology, striving for breakthroughs to better meet the health needs of the public.
As one of the society’s founders and former president, Professor Chen Siping of Shenzhen University highly praised the significance of the committee's establishment in his speech. He elaborated on the importance of minimally invasive surgery and its role in advancing medicine through examples like electromagnetic navigation bronchoscopic surgery and emphasized the cross-disciplinary integration characteristic of biomedical engineering, termed “Med+X.” Professor Chen proposed three support directions: relying on the biomedical engineering team and comprehensive talent cultivation system of Shenzhen University, strengthening committee organizational development, and leveraging Shenzhen University's achievement transformation center and investment resources to assist the committee in jointly promoting the development of minimally invasive surgery.
The establishment of the Minimally Invasive Surgery Committee of the Shenzhen Biomedical Engineering Society signifies a new stage of multidisciplinary collaborative innovation in Shenzhen's minimally invasive surgery field. In the future, the committee will lead academic-driven technological innovation, promote industry upgrades through integration, and contribute Shenzhen's wisdom and strength to the construction of a healthy China.
Summary of Achievements and Strategic Planning: Surgsci Medical Ltd. Conducts 2024-2025 Annual Symposium
At a crucial juncture of bidding farewell to the past and welcoming the new year, Shenzhen Surgsci Medical Ltd. held several meetings from January 6th to January 18th. These gatherings thoroughly reviewed the achievements and challenges of 2024 and outlined clear strategies and directions for 2025. Focused on comprehensive dialogues and in-depth planning between the marketing and R&D systems, the symposium reflected the expectations and firm beliefs of all Surgsci personnel, marking the end of the endeavors of 2024 and the beginning of a vibrant new year in 2025. The entire company worked in unity and with a shared vision, advancing together amidst opportunities and challenges in the coming year.
Marketing System: Skill Enhancement and Market Development
From January 6th to January 9th, the marketing system training and annual meeting were held at the company headquarters. This four-day event, filled with professional knowledge and skill exchange, also became a new opportunity to enhance team cohesion and combat effectiveness. The sales personnel, who had undergone a month of online training and assessment, continued to engage in professional training on dissection and surgical techniques, deepening their understanding of energy surgical instruments and ultrasonic scalpels. This was demonstrated through multiple on-site tests and group presentations.
During the practical session, the training on ultrasonic scalpel installation and troubleshooting closely integrated theory with practice, and the customer presentation and speech skills training further improved the communication and presentation abilities of the sales personnel. After the training, all sales personnel underwent professional assessments to comprehensively test their learned skills. A suturing training session on the morning of the third day elevated professional learning to a new height. Subsequently, regional directors and sales managers shared their experiences and achievements from the past year and set realistic goals for 2025. Marketing Director Lu Dawei, in his concluding remarks, emphasized the need to further consolidate the foundation, actively seek strategies, and increase coverage, providing a clear direction for the future development of the marketing team.
General Manager Feng Gengchao compared the company's departments to a football team employing the "Tiki-taka" tactic, stressing the importance of unified thinking, customer-centricity, and a core focus on delivery to build a strong all-encompassing team. After seven years of dedicated efforts, 2025 is set to be a year of significant growth for Surgsci, leading to a moment of great success.
R&D System: Innovation-Driven Progress
On January 10th to 11th, the annual R&D symposium was held as scheduled, with sales deputies from various regions attending, marking another solid step in Surgsci's journey towards business leadership and technological innovation. In his report on R&D work, General Manager Feng Gengchao reviewed the past year's achievements and challenges and raised core questions for the new year: How to continuously enhance individual competitiveness and professional qualities in the increasingly competitive market? How to create more value for others effectively? What are the fundamental purposes and deeper meanings of our work? These thought-provoking questions inspired the R&D team to constantly surpass themselves and pursue excellence, aiming to create a more brilliant future for Surgsci. In conclusion, all participants unanimously responded to General Manager Feng's questions with a firm mission—"Empower doctors, benefit patients" and the vision of "Improving people's health and quality of life."
Reports from the Regulatory Affairs, Intellectual Property, Design, and Surgical Materials & Instruments teams showcased Surgsci's profound accumulations and cutting-edge explorations in the R&D field. These achievements not only provided strong technical support for the company's development but also laid a solid foundation for future market competition.
International Sales: Expanding Markets and Achieving Win-Win Outcomes
Following the conclusion of meetings in the domestic marketing center and various R&D departments, the international sales center's market expansion strategy seminar was successfully held, injecting new momentum into Surgsci's global endeavors. Representatives from various regions comprehensively summarized and analyzed the 2024 performance, revealing market trends and in-depth changes in customer needs, providing valuable data support for sales and promotion efforts in the new year. By setting feasible goals and action plans and nearing the completion of core product and key regional entry certifications, Surgsci is set to make firm strides in the international market, promoting multi-party win-win outcomes for clients, partners, and patients.
2025: Ready for Takeoff and Creating New Success Stories
Reflecting on 2024, Surgsci achieved commendable results. At the intersection of the end and the beginning of the year, the company accumulated substantial strength with superior professional qualities and tenacious spirit for the launch in 2025. This annual symposium introduced a new model of summarization and outlook. With the successful conclusion of a series of meetings, not only were the past year's achievements and challenges comprehensively summarized, but a clear direction for the new year's journey was also outlined, uniting the consensus, goals, and thoughts of all Surgsci personnel. The meetings thoroughly discussed and addressed key issues such as "what to sell, to whom, and how to sell" and "what to do, how to do it, and achieve what"—laying a solid foundation for future development.
All Surgsci personnel will continue to uphold the noble vision of "Improving people's health and quality of life," advancing together with enthusiasm, positive attitudes, and excellent professional skills, to create a more brilliant chapter for the company in 2025!
Invitation | Join Surgsci at Arab Health 2025
As we embark on the new chapter of 2025, the global medical technology field is flourishing at an unprecedented pace. Every innovation reflects deep care and an eternal pursuit of human health. Surgsci, a rising force in providing comprehensive solutions for minimally invasive surgery, is pleased to announce and cordially invite you to join the first international event of the year in the medical technology sector—the 50th Arab Health Exhibition, to be held from January 27 to January 30, 2025, at the Dubai World Trade Center.
Event Information
Date: January 27-30, 2025
Location: Dubai World Trade Center
Surgsci Booth Number: S2.F56
Exhibition Overview
The Arab Health Exhibition, the largest and most influential healthcare event in the Middle East and North Africa, attracts thousands of exhibitors and hundreds of thousands of professional visitors from around the world each year. This exhibition is not only a high-end platform for showcasing the latest achievements in medical technology but also a critical opportunity for promoting global healthcare industry exchanges and cooperation.
International Expansion
As a global leader in providing comprehensive solutions for minimally invasive surgery, Surgsci is committed to offering innovative medical devices and technologies to advance the healthcare industry. With strong research capabilities, superior product quality, technological innovation, and excellent service, Surgsci has gained widespread recognition and trust in the international market over the years. We continue to expand our international presence, establish close cooperation with medical institutions and professionals worldwide, and drive the development of medical technology. From precise minimally invasive surgical instruments to intelligent surgical solutions, Surgsci remains at the forefront of medical technology, leading the industry's development.
Highlights
Cutting-edge Technology Showcase: Surgsci will exhibit innovative products, including the new generation ultrasonic scalpel system and balloon-type disposable laparoscopic trocar, allowing you to experience the charm of medical technology up close.
Interactive On-site Experience: Through live demonstrations and interactions, you will gain an in-depth understanding of how Surgsci products enhance surgical precision, reduce surgical risks, and provide better treatment outcomes for patients.
Global Exchange and Collaboration: During the exhibition, Surgsci will gather with healthcare professionals from around the world to discuss new trends, challenges, and opportunities in medical technology, jointly advancing the global healthcare industry.
Contact Information
If you have any questions or need further information, please feel free to contact us:
Email: service@surgsci.com
Phone: +86 755-23707593
Welcome
In 2025, Surgsci is kicking off the new year with its first appearance at the Arab Health Exhibition. This not only summarizes the efforts of the past year but also looks forward to the limitless possibilities of the future. We look forward to seeing you in Dubai, exploring the latest advancements in medical technology, sharing cutting-edge technologies, discussing collaboration opportunities, and jointly driving the healthcare industry forward.
Surgsci Conducts Annual R&D Quality Management Training
In the increasingly competitive medical device industry, Surgsci remains committed to the principle of "Quality First, Innovation Driven," continually enhancing its R&D quality management capabilities.
From December 14 to 16, Surgsci held its 2024 Annual R&D Quality Management Training at the company headquarters. The training featured lectures from senior experts Mr. Wang and Mr. Zhuang from the Shenzhen Medical Device Quality Management Association, and saw active participation from the company's R&D key personnel.
In his opening speech, General Manager Mr. Meng emphasized that medical device products are directly related to the health and lives of the people, and that the R&D team must always maintain a reverence for product quality. "Quality originates from design and is superior in production," he remarked. Through systematic training and continuous practice, he highlighted the importance of transforming quality awareness into conscious team actions, driving the high-quality development of the enterprise.
Training Highlights
On the first day, the course focused on the "Design and Development Quality Management System Process," providing an in-depth interpretation of regulatory requirements for medical device design and development. The training covered the key processes of the quality management system and explored the close connection between post-market supervision and design and development. Attendees were engaged, actively asking questions, and discussing specific issues encountered in practice with the instructors.
The second day's theme was "Medical Device Risk Management." The course systematically explained the core elements of risk management, particularly the application methods and implementation processes of DFMEA (Design Failure Mode and Effects Analysis). Discussions also covered how to integrate risk management concepts throughout the design and development process, helping attendees improve their ability to identify and control risks.
On the final day, the morning session focused on the "Registration and Certification Process." The course systematically outlined the key steps of registration and certification, clarified submission requirements, and shared practical methods for integrating registration work into the R&D phase. The afternoon session focused on the medical device quality management system, providing detailed explanations of core audit requirements, further clarifying the direction and focus of R&D quality work.
Training Summary
After three days of intensive learning, participants gained a comprehensive understanding of the core knowledge and skills in R&D quality management. Through case studies and interactive Q&A sessions, they deepened their understanding of industry regulations, design and development processes, risk management, and registration and certification. The training concluded with a unique examination, fully assessing the participants' learning outcomes.
The successful completion of this training highlights Surgsci's strong emphasis on R&D quality management and its firm commitment to talent cultivation and team building. Continuous learning and improvement have further strengthened the professional capabilities of the R&D team, laying a solid foundation for future product innovation and quality enhancement. Surgsci is poised to contribute more wisdom and strength to the development of the medical device industry with safer and more efficient innovative products.
Future Outlook
Looking ahead, Surgsci will continue to uphold its "Quality First, Innovation Driven" R&D philosophy, intensifying internal training and talent cultivation to build a high-quality, professional R&D team. The company also aims to expand cooperation and exchange within and outside the industry, promoting the high-quality development of the medical device sector. Surgsci will remain customer-focused, continually innovating and making breakthroughs to drive progress in the medical device industry.
The 31st World Endoscopic Physicians and Surgeons Alliance Forum: Pioneering New Advances in Minimally Invasive Treatment of Pancreatic Cancer
Gathering Top Experts to Explore Cutting-Edge Minimally Invasive Endoscopic Technology
The 31st World Endoscopic Physicians and Surgeons Alliance Forum concluded successfully on November 22nd in Shenzhen. Co-hosted by the World Endoscopic Physicians and Surgeons Alliance and the Second Affiliated Hospital of Shenzhen University, and organized by Surgsci Medical Ltd., the event brought together renowned experts in general surgery, hepatobiliary and pancreatic surgery, and radiology from around the globe. The forum's focus was on discussing the latest advancements in minimally invasive and endoscopic technology for the diagnosis and treatment of pancreatic cancer.
Live Surgery and Academic Lectures: Showcasing Technological Excellence
The forum was chaired by Professor He De, President of the World Endoscopic Physicians and Surgeons Alliance and Director of General Surgery at the Second Affiliated Hospital of Shenzhen University, alongside Professor Shi Xianjie, Vice President and Director of Hepatobiliary Surgery at the Eighth Affiliated Hospital of Sun Yat-sen University. Leading figures in minimally invasive surgery were invited to deliver special lectures and participate in academic discussions at the academic hall on the 3rd floor of Surgsci Medical Building. The agenda featured live surgeries and academic lectures. During the live surgery segment, Professors He De, Lu Zhenhui, and Cao Huan performed complex procedures, such as endoscopic cholecystectomy for gallstones, laparoscopic common bile duct exploration with primary suture, and fluorescence-guided cholecystectomy, demonstrating remarkable surgical skills and the advantages of minimally invasive technology.
The academic lecture segment saw experts including Professors Zhao Shuangquan, Shi Xianjie, Liao Jinqi, Li Zhiwei, Wang Weidong, and Tang Di engaging in in-depth discussions on critical topics. These included CT diagnosis and differentiation of pancreatic tumors, pancreaticogastrostomy in laparoscopic PPPD surgery, experiences with laparoscopic pancreatoduodenectomy, surgical treatment of portal hypertension, selective pericardial devascularization techniques by laparoscopy, and surgical treatment of liver cancer with portal hypertension.
Surgsci Ultrasonic Scalpel Wins High Praise from Experts
During the breaks in academic exchanges, experts visited Surgsci Medical Ltd.'s product laboratory. Here, Product Technology Manager Mr. Guo showcased the four working modes of the new generation Surgsci Ultrasonic Scalpel: Standards, Comforta, Sport, and Turbo.
Mr. Guo explained the specific applications and advantages of each mode:
Standards Mode: Rapid tissue coagulation to effectively reduce bleeding.
Comforta Mode: Significantly reduces fogging during tissue cutting, enhancing the clarity of the surgical field.
Sport Mode: Suitable for rapid cutting, improving surgical efficiency.
Turbo Mode: Designed for high-difficulty surgeries, capable of cutting through tough tissues in the shortest time.
Experts praised the innovative technology and multifunctionality of the Surgsci Ultrasonic Scalpel and expressed anticipation for its potential applications in real surgeries. Surgsci Medical Ltd.'s achievements highlight its leading position in the medical technology field and open up new possibilities for future clinical applications.
Forum Achievements Drive Innovation and Development in Minimally Invasive Medicine
The successful conclusion of this forum showcased the latest research and technological advancements in minimally invasive hepatobiliary and pancreatic medicine in China. It injected new vitality into the development of minimally invasive medicine in South China and across the country. Experts agreed that, with continuous progress and innovation in medical technology, endoscopic minimally invasive technology will play an increasingly important role in future treatments.
Strengthening Academic Exchange and Cooperation for a Healthier Future
Participants expressed their intention to use the forum as a platform to enhance academic exchange and cooperation. They aim to jointly promote innovation and development in minimally invasive technology for hepatobiliary and pancreatic diseases, bringing more benefits to patients. As a global provider of innovative solutions for intelligent consumables in minimally invasive surgery, Surgsci Medical Ltd. remains committed to popularizing minimally invasive medical technology, sharing high-quality humanistic care, and contributing to the advancement of China's medical device industry.
SURGSCI MEDICAL LTD. Triumphs at Medica 2024, Showcasing a Spectacular Display of Medical Technology
In November, the global medical industry focused its attention on Düsseldorf, Germany. From November 11 to 14, 2024, the four-day Medica 2024 exhibition, a significant global event showcasing medical equipment, concluded successfully. Exhibitors and medical experts from across the world gathered to witness this annual celebration of medical technology. SURGSCI MEDICAL LTD. (世格赛思), known for its innovative solutions in minimally invasive surgery, once again captured the spotlight, earning widespread acclaim from both domestic and international audiences.
This year’s participation marked the third consecutive invitation for SURGSCI MEDICAL LTD. at Medica. Each participation is filled with great anticipation for advancements in medical technology. The company’s international sales team brought their top products to the Düsseldorf exhibition.
Showcased products such as the SURGSCI Ultrasonic Scalpel System and Disposable Laparoscopic Trocars highlighted SURGSCI’s extensive expertise in minimally invasive technology. These innovations attracted numerous medical scholars, industry colleagues, and attendees, who were impressed by the products’ unique designs and performance.
Team members meticulously explained product features and demonstrated operations, receiving positive feedback from visitors.
Throughout the exhibition, SURGSCI engaged in in-depth interactions with customers globally, establishing solid cooperative relationships. The company reconnected with many long-standing partners and made new connections, collaboratively planning future developments.
SURGSCI’s booth featured a diverse array of products, offering a wider range of options for customers.
Long-standing customers from Portugal and Greece expressed high regard for the quality of SURGSCI’s visualized trocars and innovative balloon trocars, showing keen interest in new product collaborations. A loyal customer from Chile, known for frequent orders of ultrasonic scalpels, visited the exhibition and displayed interest in other products, planning to place new orders for ultrasonic scalpels and trocar sets. Feedback from an Iraqi customer led to prompt responses and secured an additional order.
SURGSCI’s comprehensive and diverse display left a significant impression on every visitor.
The company received abundant praise and successfully attracted cooperation interests from clients in Italy, Austria, Belgium, Iraq, Iran, South Africa, Germany, Kuwait, Algeria, Cyprus, Spain, Qatar, Poland, and Pakistan. These achievements reinforced SURGSCI’s standing in the global medical market and paved the way for future cooperation and growth.
The SURGSCI Ultrasonic Scalpel System, the company’s flagship product, once again captivated attendees. Italian customers praised its design and efficiency in addressing operational challenges. Austrian customers expressed high satisfaction after experiencing the ultrasonic scalpel heads. Belgian customers were impressed by the cutting speed of the ultrasonic scalpel. During the exhibition, SURGSCI visited several European electrosurgical companies’ headquarters, discussing technologies and development trends, leading to multiple cooperation agreements.
In the trocar segment, SURGSCI’s visualized and bladed trocars were praised for their quality. The balloon trocar, designed with a patient-centered approach, reduced surgical trauma and ensured high stability and operation, gaining unanimous praise from both domestic and international customers.
The successful conclusion of Medica 2024 showcased SURGSCI’s technology and strength and marked a significant step towards expanding into broader markets.
Through continuous technological innovation and expanded cooperation, SURGSCI aims to bring more advancements to the global medical industry, contributing significantly to patient health and well-being. The company extends sincere gratitude to all partners, customers, and supporters, whose trust and support continue to drive forward progress. SURGSCI looks forward to future collaborations to create a promising future for medical technology. See you at the next exhibition!
Surgsci Ultrasonic Scalpel System: Cross-Border Collaboration in China and South Korea with Five Live Surgeries
In several recent prominent medical events, simultaneous live surgeries were conducted in Guangdong, Fujian, and South Korea. Surgsci Medical Ltd. showcased its fully self-developed ultrasonic scalpel, assisting doctors throughout the procedures, and competing head-to-head with top international brands. This outstanding performance attracted significant attention from medical experts worldwide, highlighting the broad applications and high evaluation of Surgsci’s ultrasonic scalpel in both domestic and international medical fields.
Live Broadcast in Fuzhou: Surgsci Ultrasonic Scalpel Shines Bright
On October 25th, the 10th Multidisciplinary Standardized Treatment Seminar for Gastrointestinal Tumors commenced in Fuzhou. The following afternoon, the seminar reached its climax with the live broadcast of three total gastrectomy surgeries. Professor Chen Luchuan, the chairman of the conference, personally performed a 3D laparoscopic radical gastrectomy using the Surgsci Ultrasonic Scalpel and balloon trocar. His exceptional surgical skills, combined with the superior performance of Surgsci’s ultrasonic scalpel, resulted in an exceptionally smooth procedure with a clean surgical field and minimal bleeding. The postoperative specimen was nearly bloodless. This impeccable performance captivated the nearly thousand experts and professors present, who repeatedly inquired about the brand of the ultrasonic scalpel used and highly praised Surgsci’s product.
Surgsci Ultrasonic Scalpel (middle)
Collaborative Showcase by Minimally Invasive Surgery Experts in Shenzhen and Guangzhou: Surgsci Ultrasonic Scalpel’s Perfect Performance
From October 24th to 26th, the 18th Annual Meeting of the World Endoscopic Doctors Association Surgical Alliance and the 52nd Special Zone Hepato-Pancreato-Biliary and Gastrointestinal Surgery Forum were grandly held in Shenzhen. During this period, minimally invasive surgery experts from Shenzhen and Guangzhou conducted seven outstanding live surgeries, attracting nearly 100,000 online viewers. The Shenzhen session featured Surgsci’s flagship product, the Surgsci Ultrasonic Scalpel, throughout. Professor He De, Head of General Surgery at the Second Affiliated Hospital of Shenzhen University, performed three live surgeries, including a laparoscopic pancreatic resection. His superb surgical skills, combined with the excellent performance of the Surgsci Ultrasonic Scalpel, resulted in a magnificent surgical display.
Live Surgery in South Korea: Surgsci Ultrasonic Scalpel Competes with International Brands
On October 25th, Dr. Lee from Kyungpook National University Chilgok Hospital in South Korea tested the Surgsci Ultrasonic Scalpel against Thunderbeat. Dr. Lee conducted comprehensive tests on soft tissue, muscle, and blood vessels and gave high praise to Surgsci’s ultrasonic scalpel. He noted that despite Surgsci’s lower power compared to Thunderbeat, the cutting speed was nearly equivalent, with lower thermal damage. Additionally, Surgsci’s ultrasonic scalpel is lighter, reducing wrist fatigue during long surgeries. Dr. Lee was amazed, exclaiming, “How did they do this?”
Surgsci Ultrasonic Scalpel (left)
CEO Feng Gengchao’s Vision for the Future
In light of the continuous outstanding performance of the Surgsci Ultrasonic Scalpel, CEO Feng Gengchao stated, “This is the achievement of the Surgsci team and our initial aspiration to enter the surgical field. We have truly achieved head-to-head competition with top international brands. We are a team of engineers, and engineers always see the bugs, but we must not belittle ourselves. While maintaining high standards for ourselves, we must also dare to challenge global authorities to create even more stunning products. Our goal is to become the leader in the global surgical field, particularly in ultrasonic energy devices. This will allow us to better empower doctors and benefit patients. If we can’t achieve this goal this year, we will do it next year. Perseverance and dedication will lead us to success.”
The CEO of Surgsci Medical Ltd. Dr. Feng Gengchao
A series of recent live surgery events not only showcased the exceptional performance of the Surgsci Ultrasonic Scalpel but also further enhanced the company’s reputation and influence in the global medical community. Looking ahead, Surgsci Medical Ltd. will continue to focus on research and innovation in ultrasonic energy devices, providing advanced and efficient surgical instruments to doctors worldwide, empowering physicians, benefiting patients, and striving to improve health and quality of life globally.
Surgsci Invitation: Join Us at CMEF in Shenzhen Booth No. 12Q38
In the rapidly advancing wave of medical technology, every step forward is a profound tribute to life and health. As a pioneer in the medical field, Surgsci sincerely invites you to Shenzhen to participate in the 90th China International Medical Equipment Fair (CMEF). Let us unveil the mysteries of medical frontiers together and explore the infinite possibilities of future healthcare.
Innovative Technology, Leading the Future
The China International Medical Equipment Fair, founded in 1979, has become a global leading platform for medical health technology through over 40 years of innovation and development. This year’s CMEF is themed “Innovative Technology, Leading the Future.” Surgsci has meticulously prepared to showcase our latest technological achievements and solutions, from intelligent medical devices to precision medical technology. Each innovation will present the latest trends in the medical field, allowing you to glimpse the vast future of the industry through the details.
Collaboration and Exchange, Win-Win Opportunities
After years of development, Surgsci Medical has built a mature industrial chain, earning widespread praise and trust with excellent technological innovation and high-quality customer service. Currently, more than 1,000 hospitals and institutions nationwide have purchased our products, including ultrasonic scalpels, trocars, staplers, hemostatic clips, and sutures. With strong independent research and development capabilities, we are a leading provider of minimally invasive surgery solutions in China. Surgsci looks forward to establishing closer ties with you and many industry partners, exploring cooperation opportunities, and jointly promoting the prosperity and development of the medical industry.
Exclusive Privileges, Sincere Invitation
Dear guests, we sincerely invite you to visit Surgsci and enjoy the exclusive privileges we have carefully prepared for you. As our distinguished guest, you will receive priority access, one-on-one business consultation services, and exquisite on-site gifts. Please respond to this invitation or contact our customer service team to confirm your attendance. We will make every effort to prepare for your arrival and look forward to your visit.
Surgsci Awaits You
Please make sure to reserve time from October 12 to 15, 2024, to visit the Shenzhen International Convention and Exhibition Center. Let’s meet in Shenzhen and jointly open a new chapter in medical technology. Surgsci looks forward to working with you to continuously explore, innovate, and surpass in the journey of medical technology!
Exhibition Time: October 12-15, 2024
Exhibition Venue: Shenzhen International Convention and Exhibition Center (Bao’an New Hall)
Surgsci Booth: 12Q38
We look forward to seeing you there!
Honoring Medical Workers: Guardians of Life
In critical moments, there exists a group of individuals who transform danger into safety. Amidst the battle against the pandemic, they forge ahead without hesitation. Their unwavering commitment is fueled by reverence for life, and their dedication knows no bounds. These remarkable individuals are none other than medical workers—the sentinels of health and guardians of life.
On August 19, 2024, we celebrate the seventh “Chinese Medical Workers’ Day” under the theme of “Cherishing Humanity, Demonstrating Compassion.” On this special occasion, let us express our deepest respect for healthcare professionals who tirelessly serve on the frontlines, combating illness, racing against time, and silently dedicating themselves. To each of them, we sincerely say: Thank you!
China officially established Medical Workers’ Day in 2016, observed annually on August 19. Originating from the National Health and Health Conference, this holiday aims to promote the noble spirit of “revering life, saving the dying, assisting the injured, and boundless compassion.” It fosters a positive environment that respects medical professionals and accelerates the implementation of China’s Healthy China strategy. The State Council formally approved this holiday on November 20, 2017.
Furthermore, on August 20, 2021, the Medical Workers’ Law of the People’s Republic of China officially designated August 19 as China Medical Workers’ Day. This legal framework safeguards the rights of medical workers, regulates their professional conduct, and provides effective legal protection for China’s health strategy. The law, comprising seven chapters and 67 articles, precisely outlines the development direction and legal compliance for the medical workforce.
Since 2016, China Medical Workers’ Day has served as a guiding light for healthcare professionals. It not only acknowledges their diligent efforts but also fosters public understanding of the challenges and significance of the medical field. On this day, we collectively recognize that healthcare professionals are not merely disease fighters; they are also guardians of life. Their actions echo the noble spirit of “revering life, saving the dying, assisting the injured, and boundless compassion.”
The term “medical worker,” though succinct, carries immense weight. It signifies not only a profession but also embodies responsibility and duty. These warriors heal the wounded and safeguard the eternal flame of life. With exceptional medical skills and profound compassion, they dispel the shadows of illness, ignite the lamp of hope for rebirth, and allow the melody of health and happiness to resonate throughout humanity.
As pioneers in medical progress, these professionals navigate the vast sea of scientific research and hone their skills through clinical practice. Fearlessly exploring uncharted territories, they break through technological barriers and contribute to the edifice of medicine. They lead the charge in advancing medical technology, laying a solid foundation for the well-being of all humankind.
Simultaneously, medical workers serve as beacons of health education. Beyond physical healing, they illuminate the wisdom of the soul. Patiently imparting health knowledge, they guide the public in mastering self-care, preventing ailments proactively, and collaboratively creating a healthy and harmonious social ecosystem.
On this sacred path of service, every medical worker was once a dream-chasing youth. Bearing a divine mission within mortal bodies, they face life-and-death tests with both daring and caution. Like messengers between gods and humanity, they race against time to save lives. When the pandemic raged, they resolutely moved against the tide, embodying unwavering dedication to their calling.
On this honorable and heartwarming occasion of Medical Workers’ Day, we extend our sincere well-wishes to all healthcare professionals tirelessly serving on the frontlines. As proponents of medical innovation, Surgsci Medical Ltd. remains steadfast in our mission to empower medical workers and enhance patient care. Through state-of-the-art technology and innovative solutions, we offer robust support, enabling medical workers to diagnose and treat with greater precision and efficiency. May every endeavor by Surgsci Medical Ltd. serve as a powerful tool in the hands of these medical heroes, collectively safeguarding human health and happiness. Happy Medical Workers’ Day, and a heartfelt salute to all those who dedicate their lives to healing!
Visit our website: https://www.surgsci.com/
Email: service@surgsci.com
Opening a New Era of Minimally Invasive Surgery: Surgsci G600 AI Ultrasonic Energy Generator
In 1985, German doctor Erich Mühe successfully performed the world’s first laparoscopic cholecystectomy, marking the beginning of a new era in minimally invasive surgery. Since then, medical technology has rapidly developed in the field of minimally invasive surgery, driving revolutionary progress in medicine.
The Historical Evolution of Ultrasonic Scalpel and Minimally Invasive Surgery Technology
From the establishment of the theoretical foundation of ultrasonic energy surgical instruments in the early 20th century, to the initial exploration of minimally invasive surgery technology based on ultrasonic energy instruments, to the widespread application of ultrasonic scalpels, minimally invasive surgery technology has undergone nearly a century of research and development. Today, the ultrasonic scalpel has become a key instrument in tackling complex surgical challenges and protecting patient safety.
Entering the Era of Intelligent Medicine Driven by Big Data and AI
Today, we are stepping into a new intelligent era - an advanced medical era driven by big data, specialized precision, and AI intelligence. Each technological advancement greatly empowers the medical field, driving continuous innovation in medical technology. Surgsci, keeping up with the forefront of technology, has launched the G600 AI Ultrasonic Energy Generator, which is redefining the future of ultrasonic energy surgical instruments.
Surgsci G600 AI Ultrasonic Energy Generator: The Future of Minimally Invasive Surgery
The Surgsci G600 AI Ultrasonic Energy Generator is not only a crystallization of technological innovation, but also an important tool in medical practice to empower doctors and benefit patients. Its powerful NPU (Neural Network Processing Unit) achieves a computing power of up to 3.6TOPs per second, can monitor data changes in real-time during surgery, use AI technology for deep learning, automatically recognize, classify and process data, thereby improving the precision and safety of surgery.
AI Empowerment, Enhancing Surgical Precision and Safety
The Surgsci G600 AI Ultrasonic Energy Generator, through various AI algorithms, realizes the intelligence and automation of surgical operations:
Intelligent Algorithm for Metal Instrument Collision
Real-time monitoring of surgical instruments, similar to the “reversing radar” function. When a collision occurs, the generator identifies and alarms within 10 microseconds through the intelligent algorithm, and adjusts the energy output at the same time to ensure surgical safety.
Intelligent Control Algorithm for Low-Temperature Cutting
Precisely control energy output, maintain the optimal scalpel head temperature, reduce tissue thermal injury. At the same time, it reduces the fog during the cutting process, improving the surgical operation field of view.
Intelligent High-Temperature Warning Algorithm
Continuously monitor the temperature of the scalpel head. When the scalpel head temperature exceeds the upper limit, the system gives a warning to ensure surgical safety.
Intelligent Cutting Algorithm Adaptive to Tissue
Automatically recognize different tissues, adjust energy output, improve the precision and efficiency of surgery.
Tissue Cutting Warning Prompt Algorithm
Real-time data analysis, predict the best time for tissue cutting, automatically adjust energy, and provide operation prompts.
The application of these intelligent algorithms makes the G600 AI Ultrasonic Energy Generator provide excellent safety and precision during surgery, greatly improving surgical effects and efficiency. Through advanced AI technology, the G600 not only provides strong support for doctors but also brings higher quality medical services to patients.
Unlocking New Scenarios for Surgical Efficiency and Safety
The Surgsci G600 AI Ultrasonic Energy Generator, with its innovative functions and intelligent technology, empowers doctors, making surgery more intuitive and controllable. The application of rapid coagulation, low fog coagulation cutting, fast cutting, and super fast cutting modes optimizes surgical operations and improves patient recovery efficiency. Surgsci provides a complete set of minimally invasive medical device solutions, deeply explores clinical surgical needs, continuously pursues technological innovation, truly achieves medical technology serving the people, and improves people’s health and quality of life.
Conclusion
The Surgsci G600 AI Ultrasonic Energy Generator, as a research result of the National Key R&D Program of the Ministry of Science and Technology and the Key Technology Tackling Project of Shenzhen, is a pioneer in the combination of medical and engineering in the field of minimally invasive surgery, and is constantly promoting the development and innovation of medical technology. We are committed to enhancing the precision and safety of surgery through advanced technology and intelligent solutions, empowering doctors, benefiting patients.
Contact Us:
Email: service@surgsci.com
Website: www.surgsci.com
Clinical Classification of Bladder Tuberculosis | Surgsci
Overview:
Bladder tuberculosis, also known as tuberculosis of the bladder, is a chronic, progressive, and destructive condition caused by infection with Mycobacterium tuberculosis. It often occurs as a secondary infection following renal tuberculosis, and in rare cases, it can spread from prostatic tuberculosis. Initial symptoms include urinary frequency, which gradually worsens along with urgency, dysuria, and hematuria. Systemic symptoms such as low-grade fever and night sweats may also be present. Clinically, treatment primarily involves adequate and prolonged administration of anti-tuberculosis drugs, with surgical intervention if necessary.
Epidemiology:
Infectiousness: Bladder tuberculosis is considered non-infectious in most cases, as it is an extrapulmonary form of tuberculosis. However, if a patient has concurrent pulmonary tuberculosis, transmission can occur through respiratory routes.
High-Risk Groups:
Young adults with a history of pulmonary or renal tuberculosis.
Immunocompromised individuals.
Trends in Incidence: While authoritative data on the incidence trend of bladder tuberculosis is lacking, it is worth noting that overall tuberculosis rates have decreased due to improved living standards, environmental awareness, and vaccine promotion. However, recent increases in drug-resistant Mycobacterium tuberculosis, population mobility, and HIV prevalence have led to a resurgence of global tuberculosis cases.
Basic Etiology:
Pathogen: Bladder tuberculosis results from invasion by Mycobacterium tuberculosis, the causative agent of tuberculosis. These slender, slightly curved acid-fast bacilli are obligate aerobes with an optimal growth temperature of 37°C. Although they can affect various organs, pulmonary tuberculosis remains the most common form.
Route of Infection: Mycobacterium tuberculosis enters the bladder via the respiratory tract and subsequently disseminates through the bloodstream to the kidneys, eventually reaching the bladder via urine flow.
Risk Factors:
Poor living conditions and economic disadvantage increase the risk of infection.
Individuals with underlying conditions such as diabetes, silicosis, or whooping cough are at higher risk.
Immunosuppressed individuals or those receiving steroid or immunosuppressive therapy are also more susceptible to infection.
Typical Symptoms:
Bladder Irritation Symptoms:
Initial symptoms include urinary frequency, urgency, and dysuria.
Nocturia increases gradually, with nighttime voiding occurring 3–5 times initially and later escalating to 10–20 times.
Severe bladder mucosal damage may cause burning or painful sensations during urination.
Hematuria:
Hematuria is usually microscopic or occasionally visible as gross hematuria with clots.
Bladder contraction during voiding leads to ulceration and bleeding.
Terminal hematuria is common.
Pyuria:
Severe cases may exhibit urine containing cheesy material, appearing turbid like rice soup.
Occasionally, blood-tinged or purulent urine may be present.
Systemic Symptoms:
Patients with active systemic tuberculosis may experience fatigue, low-grade fever, and night sweats.
Complications:
Bladder Contraction:
Tuberculous bladder contraction results from severe fibrosis due to involvement of the bladder muscle layer.
Hydronephrosis:
Tuberculosis-related bladder narrowing and contraction can obstruct urine flow, leading to hydronephrosis.
Spontaneous Rupture of Tuberculous Bladder:
A late-stage complication characterized by full-thickness bladder wall involvement, resulting in caseous necrosis and thinning of affected tissue.
Patients may experience sudden abdominal pain without external trauma.
Genitourinary Tuberculosis:
Mycobacterium tuberculosis can enter the male reproductive system via the prostatic ducts, ejaculatory ducts, causing prostatitis, seminal vesiculitis, epididymitis, and orchitis.
Diagnostic Workup:
Laboratory Tests:
Urinalysis reveals acidic urine, positive urine protein, and increased red and white blood cells.
Acid-fast staining of urine sediment detects mycobacteria in approximately 50%–70% of cases.
Urine culture for tuberculous bacilli (takes 4–8 weeks) is crucial for diagnosing renal tuberculosis.
Tuberculin Skin Test:
Evaluates type IV hypersensitivity response to tuberculin antigen, indicating exposure to tuberculosis or response to BCG vaccination.
Urinary Tract Plain Film + Intravenous Urography (IVU):
Urinary Tract Plain Film (UTPF): UTPF is useful for observing bladder calcifications.
Intravenous Urography (IVU): IVU provides information about renal function, the extent of lesions, and the affected areas.
MRI:
MRI with water imaging is particularly valuable for diagnosing concurrent renal tuberculosis and assessing the presence of hydronephrosis.
Other Examinations:
Cystoscopy:
A specialized procedure involving the insertion of an instrument with a light source through the urethra to visualize changes within the bladder. Cystoscopy allows observation of bladder mucosal lesions, measurement of bladder volume, and collection of clean urine samples for further examination. Typical findings of tuberculous cystitis during cystoscopy include the formation of tuberculous nodules or varying-sized ulcerated areas on the mucosa.
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
Clinical Diagnosis And Physiological Care Of Bladder Cancer | Surgsci
Overview of Bladder Cancer
Bladder cancer refers to a malignant tumor that occurs on the bladder mucosa. It is the most common malignant tumor in the urinary system and one of the top ten common tumors in the body. It accounts for the first place in the incidence of urogenital tumors in China, and its incidence in the West is second only to prostate cancer, ranking second. In 2012, the incidence of bladder cancer in the national cancer registration area was 6.61/100,000, ranking ninth in the incidence of malignant tumors. Bladder cancer can occur at any age, even in children. Its incidence increases with age, and the high incidence age is 50-70 years old. The incidence of bladder cancer in men is 3-4 times that of women. In the past, the epithelium on the bladder mucosa was called transitional cells. In 1998, WHO and the International Urological Pathology Society jointly recommended the use of the term urothelial instead of transitional cells to distinguish it from transitional epithelium in the nasal cavity and ovaries, making urothelial a proprietary term for the urinary system. In the 2004 WHO “Pathology and Genetics of Urinary System and Male Reproductive Organs”, the histological classification of urinary system tumors includes bladder urothelial carcinoma, bladder squamous cell carcinoma, bladder adenocarcinoma, and other rare ones include bladder clear cell carcinoma, bladder small cell carcinoma, bladder-like carcinoma. The most common is bladder urothelial carcinoma, which accounts for more than 90% of the total number of bladder cancer patients. Usually, bladder cancer refers to bladder urothelial carcinoma, which was previously called bladder transitional cell carcinoma.
Causes of Bladder Cancer
The cause of bladder cancer is complex, with both inherent genetic factors and external environmental factors. The two most clear pathogenic risk factors are smoking and occupational exposure to aromatic amines. Smoking is currently the most certain risk factor for bladder cancer. 30%-50% of bladder cancer is caused by smoking. Smoking can increase the risk of bladder cancer by 2-6 times. As the smoking time prolongs, the incidence of bladder cancer also significantly increases. Another important pathogenic risk factor is related to a series of occupations or occupational exposures. It has been confirmed that aniline, diamino diphenyl, 2-naphthylamine, 1-naphthylamine are all carcinogens of bladder cancer. Long-term exposure to these chemicals increases the probability of bladder cancer. Occupational factors account for about 25% of the total number of bladder cancer patients. Occupations related to bladder cancer include aluminum products, coal tar, asphalt, dyes, rubber, coal gasification and other industries.
Clinical Manifestations
About 90% or more of bladder cancer patients initially present with hematuria, usually manifested as painless, intermittent, gross hematuria throughout the course, sometimes also as microscopic hematuria. Hematuria may only appear once or last for one day to several days, and it can alleviate or stop on its own. Sometimes the coincidence of the patient taking medicine and the cessation of hematuria often gives the patient the illusion of “cure”. Some patients may have hematuria again after a certain period of time. The color of hematuria varies from light red to dark brown, often dark red. Some patients describe it as meat washing water and tea water. The amount of bleeding and the length of hematuria are not necessarily proportional to the malignancy, size, range, and number of tumors. Sometimes when gross hematuria occurs, the tumor is already large or late; sometimes a small tumor can cause a large amount of hematuria. Some patients are found to have tumors in the bladder during health check-ups by B-ultrasound. 10% of bladder cancer patients may first present with bladder irritation symptoms, manifested as frequent urination, urgency, dysuria, and difficulty urinating, and the patient has no obvious gross hematuria. This is mostly due to tumor necrosis, ulceration, large or multiple tumors in the bladder, or diffuse infiltration of bladder tumors into the bladder wall, causing a decrease in bladder capacity or concurrent infection. Tumors in the bladder trigone and bladder neck can obstruct the bladder outlet and cause symptoms of difficulty urinating.
Clinical Diagnosis
Physical examination and past history Examine the body to determine whether the general signs of health are normal, including checking for disease markers, such as lumps or anything else that looks abnormal. The patient’s health habits, past diseases and treatment history are also part of the examination.
Internal examination For vaginal and/or rectal examination. The doctor will insert a gloved finger into the vagina and/or rectum to feel for any lumps.
Urinalysis Check the color of the urine and the substances in the urine, such as sugar, protein, red blood cells, and white blood cells.
Urine cytology examination Check the urine under a microscope to see if there are abnormal cells.
Cystoscopy Cystoscopy is inserted into the bladder through the urethra. The cystoscope is a thin tubular instrument with a light source and a mirror for observation. The cystoscope may also have tools for tissue sampling, and the tissue samples are then examined under a microscope for signs of cancer.
Intravenous pyelography (IVP) A series of X-ray examinations of the kidneys, ureters, and bladder to see if cancer is present in these organs. The contrast agent is injected into the vein, and when the contrast agent moves through the kidneys, ureters, and bladder, an X-ray examination is performed to see if there are any blockages.
Biopsy Remove part of the cells or tissues and have a pathologist look at them under a microscope to check for signs of cancer. The biopsy of bladder cancer is usually done during cystoscopy, and the entire tumor may be removed during the biopsy.
Clinical Suggestions
Surgical treatment (1) Transurethral resection (TUR) with electrocautery: A surgery that inserts a cystoscope (thin and light tube) into the bladder through the urethra. Then use a tool with a small wire loop to remove the tumor or use high-energy electric shock to burn the tumor. This is what is called electrocautery. (2) Partial cystectomy: A surgery to remove part of the bladder. This surgery is suitable for patients with low-grade cancer, and the tumor has invaded the bladder wall but is limited to part of the bladder. Because only part of the bladder is removed, the patient can urinate normally after the surgery. This is also called segmental cystectomy. (3) Radical cystectomy: A surgery to remove the bladder and any lymph nodes and nearby organs containing cancer cells. When bladder cancer invades the muscle wall, or when superficial cancer affects a large part of the bladder, this surgery can be performed. For men, the nearby organs to be removed are the prostate and seminal vesicles. For women, the uterus, ovaries, and part of the vagina will be removed. Sometimes, when the tumor has spread outside the bladder and cannot be completely removed, a surgery to remove only the bladder can be performed to reduce the urinary symptoms caused by cancer. When the bladder must be removed, the surgeon will create another way to urinate. (4) Urinary diversion: A surgery to create a new way for the body to store and excrete urine. Even if the doctor removes all the cancer cells visible during the surgery, there will still be patients who will undergo chemotherapy after the surgery to kill any possible remaining cancer cells. The treatment given after the surgery to reduce the risk of cancer recurrence is called adjuvant therapy.
Radiation therapy Radiation therapy is a type of cancer treatment that uses high-energy X-rays or other types of radiation to kill cancer cells or prevent them from growing. There are currently two types of radiation therapy. External radiation therapy uses a machine outside the body to radiate cancer. Internal radiation therapy uses radioactive substances sealed in needles, implanted particles, wires, or catheters, directly placed in and acting on cancer or near cancer. The way radiation therapy is given depends on the type and stage of the cancer being treated.
Chemotherapy Chemotherapy is a method of using drugs to stop the growth of cancer cells, either by killing the cells or by preventing the cells from dividing. When chemotherapy is given by mouth or by injection into a vein or muscle, the drug enters the bloodstream and reaches all the cancer cells in the body (systemic chemotherapy). When chemotherapy drugs are placed directly in the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs will mainly affect the cancer cells in these areas (regional chemotherapy). For bladder cancer, regional chemotherapy will be performed inside the bladder (put into the bladder through a tube inserted into the urethra).
Biological therapy Biological therapy is a treatment method that uses the patient’s immune system to fight cancer. Use substances produced by the body or in the laboratory to promote, induce, or restore the body’s natural defense mechanism against cancer. This type of cancer treatment is also called biotherapy or immunotherapy. Treatment of bladder cancer can also use BCG (Bacillus Calmette-Guerin) intravesical biological therapy. Use a catheter (thin tube) to directly put the solution containing BCG into the bladder.
Living Care for Bladder Cancer
Psychological Care Patients with bladder cancer are prone to anxiety and panic, and they may struggle to accept the reality of urinary diversion. Healthcare providers should establish a good relationship with patients, actively communicate with patients and their families, and fully earn the trust of patients. They should explain the relevant knowledge of this disease in detail, inform patients of possible complications and adverse reactions, eliminate patients’ fear, anxiety, and even despair, and encourage patients to face the disease with a positive attitude and actively cooperate with treatment.
Disease Observation Before surgery, it is important to closely observe the patient’s hematuria. After surgery, closely monitor the patient’s vital signs, continuously monitor electrocardiography, observe and record changes in the patient’s pulse, heart rate, blood pressure, etc., and ensure the smoothness of the patient’s blood transfusion and fluid infusion. Observe the wound exudation situation and change dressings in time. Regularly monitor changes in the patient’s white blood cells and body temperature, and observe whether an infection occurs. Observe the color, nature, and volume of various drainage fluids. If a large amount of bright red fluid is drained in a short period of time, the doctor should be notified in time for treatment.
Dietary Care Before surgery, patients should be given high-protein, easily digestible, and highly nutritious food. For patients with difficulty eating, intravenous nutritional support should be provided to correct anemia and improve the patient’s overall nutritional status. After transurethral bladder tumor electroresection surgery, the patient can eat 6 hours later. The diet should be rich in nutrition and coarse fiber foods, and spicy and irritating foods should be avoided.
Drainage Tube Care Different labels should be attached to various drainage tubes for distinction. The drainage tube should be properly fixed to prevent it from falling out. Keep the drainage smooth and avoid bending. Observe and record changes in the nature, color, and volume of the drainage fluid.
Pre- and Post-Chemotherapy Care If the patient’s condition allows and there is an indication for radiotherapy and chemotherapy, radiotherapy and chemotherapy will be performed half a month after surgery. Patients who can hold urine after bladder preservation surgery will immediately undergo bladder perfusion chemotherapy. Before bladder perfusion, the urine should be emptied to prevent dilution of the chemotherapy drug. After perfusion, the patient is advised to drink more water and urinate frequently to excrete the chemotherapy drug remaining in the bladder.
Company Introduction:
Shenzhen SurgSci Medical Ltd., composed of clinical experts, industry veteran sales experts, high-level talents in Shenzhen, revolves around minimally invasive surgical ultrasound scalpels, electric staplers, surgical implant medical materials, etc., adheres to the product concept of import substitution and domestic breakthrough, and carries out technology research and development. In 2019, it received investment from Shenzhen Angel Mother Fund, and completed tens of millions of strategic financing in 2020. Since its establishment, it has jointly built a medical metal material laboratory, an acoustic laboratory, a precision instrument, and measurement laboratory, and a GMP sterile clean workshop with well-known domestic universities. It has a research and development team of more than 40 people. Since its establishment, it has applied for more than 60 patents at home and abroad, including more than 20 invention patents, 2 international invention patents, and more than 30 authorized patents. It has made major breakthroughs in fine-grained titanium alloys and high-performance piezoelectric ceramic materials, resolving the risk of foreign supply cuts. It will popularize minimally invasive medical technology, share high-quality humanistic care as its mission, base itself on clinical practice, unite with universities, benefit patients, give full play to the company’s engineering technology research and development strength, continuously explore the win-win mode of medical engineering production, education, research and application, make contributions to the national medical cause, and share minimally invasive medical technology with the world.
Product Introduction
Product Name: Disposable Ureteral Stent Kit
Scope of Application: This product is suitable for connecting the human renal pelvis and bladder, and for supporting and draining the human ureter.
Manufacturer: SurgSci Medical Ltd.
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
Disposable Bladeless Visable Trocar | Surgsci
In the realm of laparoscopic surgery, the use of trocars is indispensable. These devices are used to puncture the abdominal wall, creating a pathway for surgical instruments and endoscopes. Among the various types of trocars available, disposable bladeless trocars have gained significant attention due to their unique advantages.
What is a Disposable Bladeless Trocar?
A disposable bladeless trocar is a device that features a non-bladed obturator, which seperates tissue instead of cutting it during insertion. This desin allows for smoother penetration, reducing damage to the abdominal wall and organs.
SurgSci's Bladeless Trocars:
SurgSci, a leading manufacturer of surgical instruments, has made significant strides in the development of bladeless trocars. Their products are highly regarded for their performance, quality and design.
Rapid Penetration and Reduced Damage:
One of the key advantages of SurgSci’s bladeless trocars is their ability to provide rapid penetration while minimizing damage to the abdominal wall and organs. This is achieved through the use of a bladeless tip, which separates tissue rather than cutting it.
Double Sealing Design:
Another notable feature of SurgSci’s bladeless trocars is their double sealing design. This design ensures pneumoperitoneum, a crucial aspect of laparoscopic surgery where the abdominal cavity is inflated with CO2 gas to create a working space.
Customizable Specifications:
SurgSci also offers the ability to customize the specifications of their bladeless trocars. This flexibility allows surgeons to choose the most suitable trocar for each specific procedure.
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
Distal Pancreatectomy: Procedure, Indications, and the Role of Ultrasonic Scalpel | Surgsci
A distal pancreatectomy is a surgical procedure that involves the removal of the body and tail of the pancreas. The pancreas is an organ located in the abdomen, behind the stomach, and plays a crucial role in digestion and blood sugar regulation.
This surgery is typically performed when a patient has a tumor in the body or tail of the pancreas. Tumors pose a risk of spreading to other parts of the body, and removing them from the pancreas helps reduce that risk. Other conditions that may necessitate a distal pancreatectomy include acinar cell tumors, adenocarcinoma, ampullary cancer, cancer in the lower part of the bile duct, chronic pancreatitis, duodenal cancer, inflammation, and neuroendocrine tumors.
The procedure for a distal pancreatectomy involves making an incision to expose the pancreas and spleen clearly. The surgeon then explores these organs and decides how much to remove. The remaining part of the pancreas is closed with sutures (stitches) or staples1. The surgery usually takes 2 to 4 hours.
The use of an ultrasonic scalpel in distal pancreatectomy has several advantages. An ultrasonic scalpel is a surgical instrument that uses ultrasonic vibrations to cut through tissue and coagulate blood vessels simultaneously. This technology has been found to reduce the incidence of pancreatic fistula, a significant complication of distal pancreatectomy with a rather high incidence. Pancreatic fistula occurs when pancreatic fluid leaks from the pancreas, which can lead to serious complications such as infections and bleeding.
Furthermore, using an ultrasonic scalpel without any clamping or parenchymal suturing may reduce damage to the remnant pancreas. This is crucial because even though part of your pancreas will be removed during your surgery, there’s usually enough of it left after your surgery to make hormones (insulin and glucagon) and enzymes.
In conclusion, a distal pancreatectomy is a vital surgical procedure for treating tumors and other conditions in the body or tail of the pancreas. The use of an ultrasonic scalpel in this procedure offers significant benefits, including reducing complications and preserving pancreatic function.
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
Advantages of SurgSci's Ultrasonic Scalpel in Thyroidectomy | Surgsci
A thyroidectomy is a surgical procedure that involves the removal of all or part of the thyroid gland. The thyroid is a butterfly-shaped gland located at the front of your neck. It produces hormones that regulate your body’s metabolism, from your heart rate to how quickly you burn calories. Thyroidectomy is performed to treat thyroid disorders such as cancer, noncancerous enlargement of the thyroid (goiter), and overactive thyroid (hyperthyroidism).
The use of SurgSci’s ultrasonic scalpel in thyroidectomy has several advantages:
1. Reduced operative time: The use of the ultrasonic scalpel can significantly reduce the time taken to perform the surgery.
2. Decreased postoperative pain: Patients who undergo surgery with an ultrasonic scalpel often report less pain after the operation.
3. Lower drainage volume: The use of an ultrasonic scalpel can reduce the amount of fluid that needs to be drained after surgery.
4. Prevention of transient hypocalcemia: Transient hypocalcemia, or low calcium levels in the blood after surgery, is less likely to occur when an ultrasonic scalpel is used.
5. Less instrument traffic: The ultrasonic scalpel can perform vessel sealing and tissue cutting simultaneously, reducing the need for multiple instruments.
6. Low smoke generation: The ultrasonic scalpel generates less smoke than other instruments, improving visibility during surgery.
7. Reduced lateral thermal spread and less charring: The temperature generated by the ultrasonic scalpel ranges from 50°C to 300°C, which reduces the lateral thermal spread and results in less charring.
8. Preservation of parathyroid glands: The use of an ultrasonic scalpel may facilitate dissection of the parathyroid glands in a plane farther away from the parathyroid gland capsule, thus reducing the chance of damaging their blood supply.
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
Advantages of Valveless Disposable Trocar | Surgsci
Valveless disposable trocars offer several advantages compared to trocars with valves:
1. Simplified Instrument Exchange: Valveless trocars eliminate the need for a valve mechanism, enabling easier and more efficient instrument exchange during surgical procedures. This streamlined process saves time and enhances surgical workflow.
2. Reduced Risk of Obstruction: Trocars without valves minimize the risk of valve obstruction, which can occur due to tissue or debris build-up. The absence of valves ensures unobstructed instrument passage, maintaining optimal visualization and maneuverability during the procedure.
3. Enhanced Flow and Insufflation: Valveless trocars facilitate improved fluid flow and insufflation of the surgical site. Without valves impeding the flow, trocars can maintain a continuous and steady flow of gas or fluid, enhancing the surgeon's control and visualization.
4. Cost-Effectiveness: Valveless disposable trocars often offer a more cost-effective solution compared to trocars with valves. The simplified design eliminates the need for valve components, reducing manufacturing costs. This cost-effectiveness can benefit healthcare facilities and contribute to overall cost savings.
5. Reduced Risk of Cross-Contamination: Disposable valveless trocars minimize the risk of cross-contamination between patients since there are no valve mechanisms that require cleaning and sterilization between uses. Each trocar is individually packaged, ensuring a sterile and safe surgical environment.
6. Ease of Use: Valveless trocars are generally designed to be user-friendly, with straightforward insertion and removal procedures. Surgeons and healthcare professionals appreciate the simplicity and efficiency of these trocars during minimally invasive procedures.
7. Durability and Reliability: Despite their valveless design, these trocars are typically manufactured with durable and reliable materials, ensuring their performance and functionality throughout the surgical procedure.
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
Surgsci Visible Tip Disposable Optical Trocar of 10mm for Laparoscopic Abdominal Surgery | Surgsci
The Endopass 10mm disposable optical trocar, designed for laparoscopic surgery, comes in two lengths suitable for a variety of laparoscopic procedures.
Trocar Dimensions:
Diameter: 10mm, Length: Available in 100mm and 150mm.
Additional Sizes:
5mm Optical Trocar: https://www.surgscience.com/video/products-detail-828960
12mm Optical Trocar:https://www.surgscience.com/video/products-detail-2499242
For further inquiries:
Email: service@surgsci.com
Visit our https://www.surgscience.com/
WhatsApp: +86-15826764336
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
Become Our Distributor in Your Country | SurgSci
Who are we?
SurgSci is a leading manufacturer of disposable laparoscopic instruments based in Shenzhen, China. We specialize in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels. SurgSci integrates design, R&D, manufacturing and sales. We have obtained CE & FDA and sold to nearly 30 countries in Europe, Asia, Middle East, and South America. SurgSci is looking for laparoscopic instruments’ distributors to form a lasting partnership.
SurgSci offers the following:
High quality products
Economic prices
Wide variety of product lines
OEM and ODM services
Full range of certificates
Strong product capacity
On-time delivery
R&D technical support
Great after-sales service
Who are we looking for?
SurgSci is looking for professional distributors who can cooperate with us for a long time and are committed to selling their products. We looks forward to working with you to bring our products and technologies to more people and lead a healthier life.
By becoming SurgSci’s distributor, you can help bring our high-quality products and technologies to more people around the world. You can also help improve people’s health by providing with the best possible surgical instruments.
If you are interested in becoming SurgSci’s distributor, you can check our product information and contact us to get samples. After further discussion, you can sign the distribution agreement and order the product.
To become SurgSci’s distributor, you can follow these steps:
1. Check SurgSci’s product information.
2. Contact SurgSci.
3. Get samples.
4. Further discuss with SurgSci.
5. Sign the distribution agreement.
6. Order the product.
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
Trocar Family by Surgsci | 6 Series Trocars | over 20 Different Sizes
We have been designing and manufacturing disposable laparoscopic trocars since 2017. Our current trocars cover 6 series and over 20 different sizes. Also, we can customize trocars according to your requirements.
6 Series: Optical Trocar/ Bladeless Trocar/ Bladed Trocar/ Blunt Trocar/ Hasson Trocar/ Valveless Trocar
20 Sizes: 5mm, 10mm, 12mm Trocars with 75/ 100/ 150mm Sleeves
MOQ: 1 Set
Certificates: CE, ISO, FDA
Free Samples
Looking forward to your inquiry, please contact service@surgsci.com or visit: http://www.disposabletrocar.com/ for more information.
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc.
We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485.
We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
Inside the R&D Lab | Surgsci | Laparoscopic Trocar Supplier
Take a look behind the scenes at Surgsci R&D lab in Shenzhen, China.
Here you will see some of the product development processes used by Surgsci. At present, it has about 600 square meters of research and development office space. The company adheres to the concept of making surgical operations safer, more efficient, simpler and more intelligent. It focuses on the research and development of minimally invasive surgical instruments and personalized surgical overall solutions.
For more on Surgsci visit: https://www.disposabletrocar.com/ or www.surgscience.com
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong.
Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales.
At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
7 Benefits of Neutering or Spaying Your Cats | Surgsci
1. Reduce the Number of Stray Cats
Cats have a short estrus cycle and strong reproductive ability. If the cat is not neutered or spayed, you can imagine how many kittens will be born. If the owner can't afford it and doesn't help them find a good owner, these cats will become stray cats.
It is even estimated that a pair of cats can breed 200,000 offspring in 7 years! So in order to reduce the number of stray cats, please neuter or spay the cats.
2. Disease Prevention
The sterilization of male cats can prevent many congenital genetic diseases related to the reproductive system; for female cats, it can reduce physiological diseases such as mammary glands and ovaries.
3. Reduce Estrus in Cats
Female cats start making funny noise and is more vocal than normal when they are in heat. After spaying, the excessive yowling or mating calls during estrus will be reduced.
4. Reduce Aggressiveness
Neutered male cats will be less aggressive and will not pee everywhere to mark their territory, so you don't have to smell urine all the time in your house.
5. Change the Cat's Personality
Many neutered cats will become tamer and less aggressive and stop fighting with other pets or their owners.
6. Prevent Cats from Running Away
When the estrus period comes, the cat may run away from home, or even jump off the building and get injured. The cat's appetite will suddenly increase or decrease, and the quality of sleep will also deteriorate. These conditions will be improved after sterilization.
7. Prolong Life
Neutered and spayed pets live longer, healthier, and happier lives because they have fewer behavioral problems, and they are less prone to infections, degenerative diseases, and trauma/violent death. Studies have shown that spayed female cats lived 39% longer and neutered male cats lived 62% longer.
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
https://www.surgscience.com/news-detail-1102437
Contact Us:
Email: service@surgsci.com
Website: https://www.surgscience.com/
Wechat/WhatsApp: +86-15826764336
4 Advantages Of Spaying Your Dog | Surgsci
Now more and more people keep dogs, and with more dogs, there will be more things to do. One of them is neutering or spaying your own dog. When a female dog is spayed, her ovaries and uterus are completely removed. Some veterinarians choose only to remove the ovaries of the female dog during surgery.
Some people are hesitant about this and are unsure about having the procedure. In fact, considering the many benefits after surgery, it is still necessary. So, what are the benefits of spaying female dogs? Spaying a female dog has the following benefits:
1. Spaying helps preventing them from reproducing and creating unwanted dogs or puppies
If dogs are not sterilized, it will only lead to more dogs, and eventually the number of dogs abandoned will greatly increase. The increase in the number of stray dogs will increase the probability of infecting and carrying the severe infectious disease rabies, endangering the lives of warm-blooded mammals and humans.
2. Spaying prevent uterine infections and breast cancer
Sterilization of female dogs can effectively reduce the incidence of some common diseases. Including pyometra (high incidence in female dogs over 5 years old), pseudopregnancy, alopecia, breast tumors and other common diseases, and even reduce the recurrence rate of urethral stones.
3. Spaying helps increase life expectancy
Spaying can help female dogs live longer. Studies shows that on average dogs who are neutered or spayed live one and a half years longer than those who are not. Dogs without doing spay surgery can live to be about eight years old. However, spayed dogs can live nine and a half years or more.
4. Spaying helps eliminate the troubles an anxiety during estrus
After spaying, the dog will not be overly excited, manic and other temperament changes due to estrus, and will not have much interest in other dogs. This reduces the chances of your dog straying, getting lost, fighting, getting injured and getting sick.
The pet ultrasonic scalpel Surgsci developed can bring the following benefits to pets during surgery
Quick recovery from minor wounds
Sutureless for infection prevention
Shorter surgery time to reduce anesthesia risk
Quick cuts and hemostasis to reduce bleeding
More on Surgsci ultrasonic scalpel visit: https://www.surgscience.com/products-44632
Contact Us:
Email: service@surgsci.com
Website: https://www.surgscience.com/
Wechat/WhatsApp: +86-15826764336 (Max May）
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
Electrical Lab Tour | Laparoscopic Instruments Factory | SurgSci
In the electrical lab, we have two main devices. One is a power meter, it works for the ultrasonic scalpel system. Another one is a microscope equipment, for measuring our main amplitude and transverse amplitude projects.
In the balance room, we have two analytical balances and one electronic balance. They are used to measure precision reagents. We also have a high temperature blast drying oven, mainly used to measure evaporation residue.
There are also two fume hoods and a water bath. The water bath is used for the configuration of strong acid, alkali reagents and testing. In our gas chamber is a cylinder cabinet, an air generator, a hydrogen generator, a gas chromatograph, a headspace sampler, computers and a printer. We also have equipment for measuring EO residue.
We store chemical reagents and cluture medium in reagent room. We have a lure tester is for testing the auxiliary gas valve interface project. The tensile machine measures firmness, tensile elongation, fixed trength and other items.
For more of our factory laboratory introduction:
Microbiology Lab:https://www.surgscience.com/video/products-detail-1318571
Sterile Room and Microbial Containment Room:https://www.surgscience.com/news-detail-1322105
Positive Control Lab:https://www.surgscience.com/news-detail-1333320
Physical and Chemical Lab:https://www.surgscience.com/news-detail-1382633
For more information, please visit our website:https://www.surgscience.com/https://www.disposabletrocar.com/
Contact Us:
Email: service@surgsci.com
Wechat/WhatsApp: +86-15826764336
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
How to Use a Hasson Trocar | Instructions for Use | SurgSci
1. Take the obturator and cannula out of the box using sterile technique.
2. Create an incision and ensure the abdominal cavity has been entered (refer to Hasson abdominal entry skill).
3. Pass two sutures through each fascial edge, assemble the obturator and cannula, insert the trocar into the cavity with suture lie post secured on the cannula.
4. Wrap the suture line around each suture tie post to make the cannula stable on the abdomen, unlock the cam on suture tie post to adjust cannula position in abdominal cavity.
5. Lock the suture tie post, press both locking buttons on the obturator top and release the obturator from cannula.
6. Connect the gas line and open the stopcock to make pneumoperitoneum, then insert surgical instruments through cannula for operation.
7. Push the outer seal release lever on the cannula to release the outer seal for specimen removal procedure during surgery.
8. Remove the gas line, loose sutures on the suture lie post, take out the cannula and suture the cavity.
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
SurgSci Wishes Everyone a Happy New Year
Dear clients, we sincerely wish you all a Happy New Year! There is no better gift for us than to see you satisfied and happy. We wish you the realization of your goals, inspiration, warmth, joy and more memorable events! Let's not stop there, because in the new year only luck and success await us. Happy new year!
For more information, please visit our website:
https://www.surgscience.com/
https://www.disposabletrocar.com/
Contact Us:
Email: service@surgsci.com
Wechat/WhatsApp: +86-15826764336
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
What is a Surgical Linner Cutter Stapler? | Surgsci
Surgical staplers and staples are medical devices that may be used in place of sutures. They are often used in minimally invasive surgery, such as gastrointestinal anastomosis. They can close large wounds or incisions more quickly and be less painful than stitches for patients. It is similar to traditional manual suturing. But with the addition of modern technology, it has a very significant effect in clinical use. The main working principle is to used large nails to its tissue is cut or anastomosed, and its function is more like a stapler. According to the scope of application, it can be divided into skin staplers, rectal staplers, and blood vessel staplers.
The cutter stapler has the following advantages:
1. Use titanium nails or stainless steel nails to suture tightly and moderately tight.
2. It is a one-time use to avoid cross-infection.
3. Fewer side effects and less surgical complications.
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
'INT J BIOL MACROMOL'——SurgSci's First High-Level SCI Article Year 2023
Recently, the biomedical materials R&D team of Shenzhen SurgSci Medical Ltd. made a research achievement titled "Hyaluronic acid and chitosan-based injectable and self-healing hydrogel with inherent antibacterial and antioxidant bioactivities" was published in the international SCI academic journal "INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES" (Chinese Academy of Sciences SCI Journal Area 1, IF=8.025, TOP journal).
Based on natural biomacromolecules, quaternary ammonium chitosan (QCS), tannic acid (TA) and oxidant hyaluronic acid (OHA), a new product called QCS-l-TA-l-OHA was developed. The hydrogel dressing ("l" is "link"), whose research inspiration comes from natural substances such as quaternary ammonium chitosan (QCS), tannic acid (TA), oxidant hyaluronic acid (OHA) and their derivatives The antibacterial, antioxidative and wound healing functions of the substance have fully exerted the biological activity of the new intelligent multifunctional hydrogel, a natural substance and its derivatives, and has broad application prospects for the development of the biomedical field.
In order to study the intrinsic antibacterial and antioxidant biological activities of the dressing, the team members designed the molecular structure of the QCS-l-TA-l-OHA hydrogel and used the hydrogel as a rat full-thickness skin incision model wound. The dressing is composed of QCS, OHA, TA and the cross-linked bonds of the polymer network to build a chemical structure. Under the action of dynamic imine bonds and multiple hydrogen bonds between the amino groups on QCS and the aldehyde groups on OHA, The PBS solution of OHA and QCS containing TA formula (TA + OHA) were respectively filled into a double-barreled syringe, and injected directly into the target wound at the same time, and it was concluded that the hydrogel can quickly gel in situ and seamlessly fill and fit The results of irregular wounds have further verified that hydrogel is beneficial to promote the rapid healing of various skin wounds and physiological wounds, and avoid patients from excessive use of antibiotics or antioxidants in a long treatment cycle, which is an urgent need for clinical wound management provided important support.
In order to evaluate the in vivo gelation formation ability of QCS-l-TA-l-OHA hydrogel, the team members subcutaneously injected the precursor polymerization solution in the back of rats to realize in situ gelation, and the gelation could maintain enough completeness and strength. The healing-accelerating performance of QCS-l-TA-l-OHA hydrogel was evaluated through a full-thickness wound defect model, which proved that it has excellent antibacterial, antioxidative and wound healing abilities.
QCS-l-TA-l-OHA hydrogel significantly promotes wound healing in rat skin full-thickness incision model
The SurgSci team further analyzed the therapeutic effect of the hydrogel on living skin wounds by H&E histological staining. The results showed that the TA added in the QCS-l-TA-l-OHA hydrogel has antibacterial and antioxidant effects, and is better for It is very important to improve skin wound healing, and the hydrogel has a significant therapeutic effect on granulation tissue thickening.
QCS-l-TA-l-OHA has good results in the evaluation of skin tissue repair
QCS-l-TA-l-OHA hydrogel, as a novel biological substance, can be administered in vivo by endoscope or injected by injection needle in clinic, which can provide minimally invasive treatment and local specific wound care to some extent. The treatment has opened up a new way and brought new gospel to the biomedical community. In the future, QCS-l-TA-l-OHA hydrogel is expected to become a new type of biomaterial for wound healing.
About Surgsci
Surgsci Medical Ltd. aims to improve people's health and quality of life. We adhere to the mission of independent research and development, popularize minimally invasive medical technology, and share high-quality humanistic care. Through clinical practice, we innovate in technology to benefit patients, medical staff, and medical institutions. We provide holistic innovative solutions for hepatobiliary and gastrointestinal surgery, ENT surgery, colorectal surgery, bariatric surgery, oncology, urology, thoracic surgery, women's and children's surgery, neurosurgery, etc. We are in Shenzhen, Guangdong. Founded in 2017, Surgsci is a national high-tech enterprise, focusing on the innovation for smart consumables for minimally invasive surgery. We are specialized in the production of laparoscopic surgical instruments, including disposable laparoscopic trocars and ultrasonic scalpels etc. We own two factories in Pingshan and Bao’an District, a total of about 1500 square meters of R&D office and 4000 square meters of GMP clean workshop with ISO13485. We integrate design, R&D, manufacturing, and sales. At present, we have more than 40 authorized patents at home and abroad. The products have obtained CE & FDA and are sold to nearly 30 countries in Europe, Asia, the Middle East, and South America. We Provide high quality OEM and ODM services which are recognized and favored by our customers. Looking forward to your inquiry and cooperation.
Video
